• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Hollis-Eden Pharmaceuticals Announces Third Quarter 2005 Conference Call and Investor Conference Webcast

Posted on: Monday, 31 October 2005, 09:01 CST

Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today announced that it has scheduled the following conference call and webcasts:

-- Third Quarter 2005 Conference Call and Webcast November 3, 2005 at 12:30 p.m. Eastern (9:30 a.m. Pacific). Hollis-Eden will release financial results prior to the market opening that day. The conference call can be accessed by dialing 800-659-2037 (domestic) or 617-614-2713 (international) and requesting the Hollis-Eden conference call. A live webcast of the conference call will be available under "Event Calendar" on the Investors section of Hollis-Eden's website at www.holliseden.com. The webcast will be archived at the Company's website for 30 days, and a replay of the call will be available by phone for 24 hours beginning approximately one hour after the call is completed, and can be accessed at 888-286-8010 (domestic) or 617-801-6888 (international), passcode 97951936.

-- Rodman and Renshaw Techvest Annual Healthcare Conference in New York on November 8, 2005, 9:25 a.m. Eastern (Richard B. Hollis, Chairman and CEO, presenting.) A live webcast will be available from this conference, and may be accessed under "Event Calendar" on the Investors section of Hollis-Eden's website at www.holliseden.com. The webcast will be archived at the Company's website for 30 days.

Hollis-Eden Pharmaceuticals

Hollis-Eden Pharmaceuticals, Inc. is a development-stage pharmaceutical company based in San Diego, California, working to become the world leader in the development of a new class of investigational drugs known as immune regulating hormones (IRHs). The goal of IRH therapy is to direct, through controlling gene expression, the production of key cytokines and enzymes that re-regulate immune and metabolic functions toward homeostasis, a profile that could be useful in a wide variety of diseases. The Company has a number of investigational compounds under development, including NEUMUNE(TM), which the Company is developing for use in protection from Acute Radiation Syndrome (ARS); PHOSPHONOL(TM), a non-IRH candidate for providing protection against DNA mutations from radiation exposure and chemotherapy treatment; and IMMUNITIN(TM), which has shown activity in a variety of infectious diseases, including HIV/AIDS, tuberculosis and malaria. Hollis-Eden is also developing IRHs for protection from chemotherapy and other conditions of immune dysregulation such as autoimmunity. For more information on Hollis-Eden, contact the Company's website at www.holliseden.com.

This press release contains forward-looking statements concerning the potential and prospects of the Company's drug discovery program and its drug candidates. Any statement describing a goal, expectation, intention or belief of the Company is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including the ability to complete preclinical and clinical trials successfully and within specified timelines, if at all; the ability to obtain regulatory approval for NEUMUNE under the U.S. Food and Drug Administration Animal Efficacy Rule, even if shown to be effective in preclinical studies; the ability to receive any stockpiling orders for NEUMUNE from the U.S. and foreign governments, even if approved by regulatory authorities; the Company's future capital needs; the Company's ability to obtain additional funding; the ability of the Company to protect its intellectual property rights and to not infringe the intellectual property rights of others; the development of competitive products by other companies; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release.

Source: Business Wire

More News in this Category